Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 16, 2020 - Issue
Submit an article Journal homepage
434
Views
14
CrossRef citations to date
0
Altmetric
Review

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines

M D Benson1 Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USACorrespondence[email protected]
,
N R Dasgupta1 Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA;2 Division of Cardiology, Indiana University School of Medicine, Indianapolis, IN46040, USA
&
R Rao2 Division of Cardiology, Indiana University School of Medicine, Indianapolis, IN46040, USAORCID Iconhttps://orcid.org/0000-0002-1750-389X
ORCID Icon
Pages 749-758 | Published online: 14 Aug 2020

References

  • Benson MD, Buxbaum JN, Esienberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–219. doi:10.1080/13506129.2018.1549825
  • Thomas VE, Smith J, Benson MD. Amyloidosis: diagnosis and new therapies for a misunderstood and underdiagnosed disease. Neurodegener Dis Manag. 2019;9(6). doi:10.2217/nmt-2019-0020
  • Maurer MS, Bokhari S, Dorbala S, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9). doi:10.1161/CIRCHEARTFAILURE.119.006075.
  • Wittles RM, Bokhari S, Thibaud D, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. J Am Coll Cardiol HF. 2019;7:709–716.
  • Adams D, Ando Y, Melo Beirao J, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020. doi:10.1007/s00415-019-09688-0
  • Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594. doi:10.1093/eurheartj/ehv338
  • Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis. JACC. 2019;74(21):2638–2651. doi:10.1016/j.jacc.2019.09.056
  • Carvalho A, Rocha A, Lobato L. Liver Transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl. 2015;21(3):282–292. doi:10.1002/lt.24058
  • Sousa M, Mohan G, Guglin M, et al. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017;22:317–327. doi:10.1007/s10741-017-9601-z
  • Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. NEJM. 2018;379:11–21. doi:10.1056/NEJMoa1716153
  • Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. NEJM. 2018;379:22–31. doi:10.1056/NEJMoa1716793
  • Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431–443. doi:10.1161/CIRCULATIONAHA.118.035831
  • Dasgupta NR, Rissing SM, Smith J, et al. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27(1):52–58. doi:10.1080/13506129.2019.1685487
  • Judge DP, Kristin AV, Grogen M, et al. Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy. Cardiovasc Drugs Ther. 2020;1–14.
  • Janas MM, Zlatev L, Liu J, et al. Safety of 2ʹ-deoxy-2ʹ-flouro nucleotides in GalNAc-siRNA conjugates. Nucleic Acids Res. 2019;47(7):3306–3320. doi:10.1093/nar/gkz140
  • Maurer MS, Schwartz JH, Gundapaneni MS, et al. Tafamidis treatment for patients with Transthyretin Amyloid Cardiomyopathy. NEJM. 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689
  • Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis for transthyretin amyloid cardiomyopathy. Circulation. 2020;141(15):1214–1224. doi:10.1161/CIRCULATIONAHA.119.045093
  • Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy. JAMA. 2013;310(24):2658–2667. doi:10.1001/jama.2013.283815
  • Graham L, Pipilas A, Mussinelli R, et al. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2019.
  • Schwarzlow C, Kazamel M. Hereditary transthyretin amyloidosis: clinical presentation and management updates. J Clin Neuromuscul Dis. 2020;21:144–156. doi:10.1097/CND.0000000000000270
  • Coelho T, Maia LF, da Silva A. Tafamidis for transthyretin familial polyneuropathy: a randomized controlled trial. Neurology. 2012;79(8):785–792. doi:10.1212/WNL.0b013e3182661eb1
  • Waddington Cruz M, Benson MD. A review of tafamidis for the treatment of transthyretin- related amyloidosis. Neurol Ther. 2015;4(2):61–79. doi:10.1007/s40120-015-0031-3

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.